+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase-type plasminogen activator uPA and its inhibitor PAI-1 in cancer of the upper GI-tract



Urokinase-type plasminogen activator uPA and its inhibitor PAI-1 in cancer of the upper GI-tract



Journal of Cancer Research & Clinical Oncology 120(Suppl. ): R46




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144274

Download citation: RISBibTeXText


Related references

Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells: Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. European Journal of Biochemistry 233(2): 514-519, 1995

Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Annals of Surgical Oncology 10(8): 948-953, 2003

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Research & Treatment. 49(1): 41-50,, 1998

Urokinase-type plasminogen activator , urokinase-type plasminogen activator receptor , plasminogen activator inhibitor type 1 , type 2 , and tissue-type plasminogen activator in breast cancer cells. Fibrinolysis & Proteolysis 14(Suppl. 1): 38, 2000

Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Oncology Reports 17(5): 1259-1268, 2007

Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 82(4): 724-732, Feb 15, 1998

Increased concentration of tissue plasminogen activator/plasminogen activator inhibitor type 1 complex and urokinase plasminogen activator in cytosols of early stage of malignant breast cancer. Blood 90(10 Suppl. 1 Part 2): 94B, Nov 15, 1997

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Research 54(10): 2527-2530, 1994

Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clinical Chemistry 48(8): 1288-1295, 2002

gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. Journal of Cell Science 108: 2361-2368, 1995

Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression. Molecular & Cellular Endocrinology 133(2): 109-116, Oct 20, 1997

Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. Pathology International 50(5): 392-397, 2000

Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression. American Journal of Clinical Pathology 128(3): 404-413, 2007

Estradiol regulation of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in MDA-MB-231 breast cancer cells stably expressing the estrogen receptor. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 412, 1997

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Cancer Research 62(16): 4617-4622, August 15, 2002